• Covidien (Hamilton, Bermuda) said that its surgical devices business unit has received FDA clearance to market the Covidien SILS procedure kit, indicated for single-incision laparoscopic surgery and other advanced laparoscopic procedures. The devices in the kit can be used by surgeons to perform laparoscopic procedures through a single skin incision located within the patient's umbilicus, or belly button. The kit features several advanced articulating instruments and access ports, which enable improved access to the surgical site and maneuverability for tissue dissection and retraction. Covidien makes product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies.
  • Instrumentarium Dental reported introduction of the Soredex Scanora 3-D X-ray system with HD panoramic. Soredex Scanora 3-D combines a cone beam with high definition panoramic imaging in a single system to produce anatomically correct images of teeth, bone and soft tissue plus the highest quality panoramic images. In cone beam mode, Scanora 3-D offers three fields of view allowing the proper image volume to be selected for each specific diagnostic task. The field of view can be positioned anywhere within the maxillofacial area. The smallest view is 60 mm x 60 mm and is ideal for single implant operations, localized dental problems and TM joints. The medium view, 75 mm x 100 mm, is suitable when the entire dentition, including the mental and mandibular foramen, needs to be examined. The largest view, 75 mm x 145 mm, is the best choice when the complete dentition, both TM joints and upper cervical spine, or maxillofacial area, with airways, must be examined. Instrumentarium Dental makes dental imaging equipment.
  • Sangart (San Diego) said it has completed enrollment in the second Phase III trial of its lead product, Hemospan. The trials were designed to evaluate the safety and efficacy of Hemospan for preventing and treating hemodynamic instability, particularly hypotension, or low blood pressure, during primary hip-replacement surgery. Sangart is focused on the development and commercialization of therapeutic oxygen transport agents.